Show simple item record

dc.creatorLandais, E
dc.creatorMurrell, B
dc.creatorBriney, B
dc.creatorMurrell, S
dc.creatorRantalainen, K
dc.creatorBerndsen, ZT
dc.creatorRamos, A
dc.creatorWickramasinghe, L
dc.creatorSmith, ML
dc.creatorEren, K
dc.creatorde Val, N
dc.creatorWu, M
dc.creatorCappelletti, A
dc.creatorUmotoy, J
dc.creatorLie, Y
dc.creatorWrin, T
dc.creatorAlgate, P
dc.creatorChan-Hui, PY
dc.creatorKarita, E
dc.creatorWard, AB
dc.creatorWilson, IA
dc.creatorBurton, DR
dc.creatorSmith, D
dc.creatorPond, SLK
dc.creatorPoignard, P
dc.date.accessioned2021-01-22T14:40:52Z
dc.date.available2021-01-22T14:40:52Z
dc.date.issued2017-11-21
dc.identifier.issn1074-7613
dc.identifier.issn1097-4180
dc.identifier.doihttp://dx.doi.org/10.34944/dspace/4831
dc.identifier.other29166592 (pubmed)
dc.identifier.urihttp://hdl.handle.net/20.500.12613/4849
dc.description.abstract© 2017 The Authors Understanding how broadly neutralizing antibodies (bnAbs) to HIV envelope (Env) develop during natural infection can help guide the rational design of an HIV vaccine. Here, we described a bnAb lineage targeting the Env V2 apex and the Ab-Env co-evolution that led to development of neutralization breadth. The lineage Abs bore an anionic heavy chain complementarity-determining region 3 (CDRH3) of 25 amino acids, among the shortest known for this class of Abs, and achieved breadth with only 10% nucleotide somatic hypermutation and no insertions or deletions. The data suggested a role for Env glycoform heterogeneity in the activation of the lineage germline B cell. Finally, we showed that localized diversity at key V2 epitope residues drove bnAb maturation toward breadth, mirroring the Env evolution pattern described for another donor who developed V2-apex targeting bnAbs. Overall, these findings suggest potential strategies for vaccine approaches based on germline-targeting and serial immunogen design. Understanding the molecular basis of HIV Env-specific broadly neutralizing antibodies (bnAbs) development is key for vaccine design. Landais et al. find that glycan heterogeneity played a role in the activation of V2 apex PCT64 bnAbs precursor and that viral evolution was similar to CAP256, another donor with V2 apex bnAbs.
dc.format.extent990-1003.e9
dc.language.isoen
dc.relation.haspartImmunity
dc.relation.isreferencedbyElsevier BV
dc.rightsCC BY-NC-ND
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectAIDS Vaccines
dc.subjectAntibodies, Neutralizing
dc.subjectCell Lineage
dc.subjectComplementarity Determining Regions
dc.subjectHIV Antibodies
dc.subjectHumans
dc.subjectenv Gene Products, Human Immunodeficiency Virus
dc.titleHIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody Lineage
dc.typeArticle
dc.type.genrePost-print
dc.relation.doi10.1016/j.immuni.2017.11.002
dc.ada.noteFor Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu
dc.creator.orcidPond, Sergei L. Kosakovsky|0000-0003-4817-4029
dc.date.updated2021-01-22T14:40:47Z
refterms.dateFOA2021-01-22T14:40:52Z


Files in this item

Thumbnail
Name:
HIV Envelope Glycoform Heterog ...
Size:
2.960Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

CC BY-NC-ND
Except where otherwise noted, this item's license is described as CC BY-NC-ND